NewLink Genetics Corporation (NASDAQ:NLNK)‘s stock had its “buy” rating restated by analysts at Cantor Fitzgerald in a note issued to investors on Thursday. They presently have a $26.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 177.78% from the stock’s previous close.

The analysts wrote, “Path Forward in Melanoma. Indoximod is expected to enter a pivotal Phase III trial in combination with both Keytruda and Opdivo, with a planned enrollment of 600 patients. The trial design aims to compare PD-1 monotherapy to combination treatments, with co-primary endpoints of overall survival (OS) and progression free survival (PFS).””

A number of other equities research analysts have also recently weighed in on the company. Bank of America Corporation assumed coverage on NewLink Genetics Corporation in a research note on Friday, October 13th. They set a “buy” rating and a $22.00 price objective for the company. ValuEngine cut NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Stifel Nicolaus upped their price objective on NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Robert W. Baird upgraded NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and increased their price target for the company from $8.00 to $22.00 in a research note on Friday, September 8th. Finally, Jefferies Group LLC upgraded NewLink Genetics Corporation from a “hold” rating to a “buy” rating and increased their price target for the company from $7.00 to $26.00 in a research note on Friday, September 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $25.83.

ILLEGAL ACTIVITY WARNING: “NewLink Genetics Corporation (NLNK) Given Buy Rating at Cantor Fitzgerald” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/02/newlink-genetics-corporation-nlnk-given-buy-rating-at-cantor-fitzgerald.html.

In other news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the business’s stock in a transaction dated Friday, October 6th. The shares were acquired at an average cost of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the acquisition, the insider now owns 7,857,732 shares of the company’s stock, valued at $80,541,753. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 13.70% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. acquired a new stake in NewLink Genetics Corporation during the third quarter worth about $963,000. The Manufacturers Life Insurance Company grew its holdings in NewLink Genetics Corporation by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 556 shares during the period. State Street Corp grew its holdings in NewLink Genetics Corporation by 1.2% during the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after acquiring an additional 4,630 shares during the period. Tudor Investment Corp ET AL acquired a new stake in NewLink Genetics Corporation during the second quarter worth about $286,000. Finally, PDT Partners LLC boosted its position in NewLink Genetics Corporation by 160.2% during the second quarter. PDT Partners LLC now owns 115,795 shares of the biotechnology company’s stock worth $851,000 after purchasing an additional 71,295 shares in the last quarter. 55.09% of the stock is currently owned by hedge funds and other institutional investors.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.